Cefsulodin

Cefsulodin
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	J01DD03 (WHO) ;
Identifiers
	IUPAC name 4-(aminocarbonyl)-1-[((6R,7R)-2-carboxy-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]pyridinium;
CAS Number	62587-73-9 ; Sodium salt: 52152-93-9 ;
PubChem CID	5284530;
ChemSpider	4447588 ;
UNII	OV42LHE42B; Sodium salt: 2D087186PY ;
KEGG	D02005 ;
ChEMBL	ChEMBL1617285 ;
CompTox Dashboard (EPA)	DTXSID6022769 ;
Chemical and physical data
Formula	C22H21N4O8S2+
Molar mass	533.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(c3ccccc3)S(=O)(=O)O)C[n+]4ccc(C(=O)N)cc4)C([O-])=O;
	InChI InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17?,21-/m1/s1 ; Key:SYLKGLMBLAAGSC-IKZMBGHXSA-N ;
	(what is this?) (verify)

Cefsulodin is a third-generation cephalosporin antibiotic that is active against Pseudomonas aeruginosa and was discovered by Takeda Pharmaceutical Company in 1977.^[1]^[2]^[3]^[4]

TAP Pharmaceuticals had a new drug application on file with FDA for cefsulodin under the brand name Cefonomil as of 1985.^[5]

Cefsulodin is most commonly used in cefsulodin-irgasan-novobiocin agar to select for Yersinia microorganisms.^[6] This agar is most often used in water and beverage testing.^{[citation needed]}

Susceptibility data

The following represents MIC susceptibility data for various P. aeruginosa strains:^[7]

Pseudomonas aeruginosa PA13 (resistant strain): 32 μg/ml
Pseudomonas aeruginosa (wild-type, susceptible): 4 - 8 μg/ml

References

^ "TOKU-E Technical Application Sheet" (PDF). Archived from the original (PDF) on 27 September 2011.
^ Smith BR (1984). "Cefsulodin and ceftazidime, two antipseudomonal cephalosporins". Clinical Pharmacy. 3 (4): 373–85. PMID 6380902.
^ Neu HC, Scully BE (1984). "Activity of cefsulodin and other agents against Pseudomonas aeruginosa". Reviews of Infectious Diseases. 6 (Suppl 3): S667–77. doi:10.1093/clinids/6.supplement_3.s667. PMID 6443768.
^ Wright DB (November 1986). "Cefsulodin". Drug Intelligence & Clinical Pharmacy. 20 (11): 845–9. doi:10.1177/106002808602001104. PMID 3536385. S2CID 243377437.
^ "Lupron Is First Abbott-Takeda Product to Reach U.S. Market". Pink Sheet. 15 April 1985.
^ "BAM Media M35: Cefsulodin-Irgasan Novobiocin Agar or Yersinia Selective Agar". Food and Drug Administration. Retrieved 2 September 2012.
^ "Cefsulodin | the Antimicrobial Index Knowledgebase - TOKU-E".

[racgp-1] "TOKU-E Technical Application Sheet" (PDF). Archived from the original (PDF) on 27 September 2011.

[Smith_1084-2] Smith BR (1984). "Cefsulodin and ceftazidime, two antipseudomonal cephalosporins". Clinical Pharmacy. 3 (4): 373–85. PMID 6380902.

[Neu_1984-3] Neu HC, Scully BE (1984). "Activity of cefsulodin and other agents against Pseudomonas aeruginosa". Reviews of Infectious Diseases. 6 (Suppl 3): S667–77. doi:10.1093/clinids/6.supplement_3.s667. PMID 6443768.

[Wright_1986-4] Wright DB (November 1986). "Cefsulodin". Drug Intelligence & Clinical Pharmacy. 20 (11): 845–9. doi:10.1177/106002808602001104. PMID 3536385. S2CID 243377437.

[5] "Lupron Is First Abbott-Takeda Product to Reach U.S. Market". Pink Sheet. 15 April 1985.

[6] "BAM Media M35: Cefsulodin-Irgasan Novobiocin Agar or Yersinia Selective Agar". Food and Drug Administration. Retrieved 2 September 2012.

[7] "Cefsulodin | the Antimicrobial Index Knowledgebase - TOKU-E".

[1]

[2]

[3]

[4]

[5]

[6]

[7]